Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Products, services, technology

Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD).

Cooperation possibilities

R&D, co-development, licensing.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2014
  • Number of employees in Switzerland
    10-19
Key business